Doxazosin Tablet
Product Images NDC 70518-3667

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 70518-3667). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm1 (Doxazosin 2mg 70518 3667 00)

Mm1 (Doxazosin 2mg 70518 3667 00)
Label for Doxazosin 2 mg oral tablets provided by RemedyRepack Inc. The label indicates a quantity of 30 tablets in the package and repackaging by RemedyRepack Inc., Indiana, PA. The manufacturer is Apotex Corp., Weston, FL. The label includes an NDC number, barcode, and QR code along with storage instructions.*
FDA Label Image

Doxazosin-structure.jpg (Doxazosin Structure)

Doxazosin-structure.jpg (Doxazosin Structure)
Chemical structure of doxazosin mesylate, illustrating its molecular arrangement including the methoxy-substituted aromatic rings, piperazine ring, and the mesylate group.*
FDA Label Image

Figure1.jpg (Figure1)

Figure1.jpg (Figure1)
This image shows two line graphs comparing the effects of Doxazosin versus placebo during a 14-week treatment period. The first graph illustrates the mean change in total symptom score from baseline, showing a greater reduction with Doxazosin. The second graph depicts the mean increase in maximum urinary flow rate from baseline, with Doxazosin showing a higher increase. Both graphs include sample sizes and statistical significance markers.*
FDA Label Image

Table3.jpg (Table3)

Table3.jpg (Table3)
A data table summarizing effectiveness data from placebo-controlled clinical trials of Doxazosin, showing symptom scores and maximum flow rate changes in three studies with various doses (4 mg, 8 mg). Adjacent bar graph depicts differences in symptom score and maximum flow rate between placebo and Doxazosin doses, highlighting statistically significant improvements for Doxazosin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.